Juno Therapeutics Obtains $31,000,000 Series A Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a4924a68-cd85-44c3-91f7-3a276746acd3
Date
4/24/2014
Company Name
Juno Therapeutics
Mailing Address
307 Westlake Avenue North Seattle, WA 98109 USA
Company Description
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Website
http://www.junotherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$31,000,000
Transaction Round
Series A
Proceeds Purposes
Juno’s initial funding of $120 million came predominantly from leading technology venture capital firm ARCH Venture Partners and the Alaska Permanent Fund, through a partnership managed by Crestline Investors. The completion of the A round includes expansions from founding investors as well as investments from Bezos Expeditions, the personal investment company of Jeff Bezos, and Venrock, amongst others.
M&A Terms
Venture Investor
Venture Investor
Venture Investor